Products & Services · Contract with Customer, Liability, Current
Paxlovid and Comirnaty — Contract with Customer, Liability, Current
Pfizer Paxlovid and Comirnaty — Contract with Customer, Liability, Current decreased by 6.2% to $646.00M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026
Rolls up toDeferred Revenue
How to read this metric
Higher values indicate a robust pipeline of near-term revenue realization, whereas lower values suggest a potential decline in short-term product delivery volume.
Detailed definition
This represents the portion of contract liabilities related to specific pharmaceutical products that is expected to be r...
Peer comparison
Comparable to 'Current Contract Liabilities' reported by other large-cap pharmaceutical firms managing multi-year supply contracts.
Metric ID:
pfe_segment_paxlovid_and_comirnaty_contract_with_customer_liability_currentHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $689.00M | $646.00M |
| QoQ Change | — | -6.2% |
Range$646.00M – $689.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's paxlovid and comirnaty — contract with customer, liability, current?
- Pfizer (PFE) reported paxlovid and comirnaty — contract with customer, liability, current of $646.00M in Q1 2026.
- What does paxlovid and comirnaty — contract with customer, liability, current mean?
- The portion of advance customer payments expected to be recognized as revenue within one year.